Abstracts tagged "Inflammation"

Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Philip Mease¹, Ana-Maria Orbai², Oliver FitzGerald³, Mohamed Bedaiwi⁴, Dona L Fleishaker⁵, Rajiv Mundayat⁶, Pamela Young⁷ and Philip S Helliwell⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…
Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
Abstract Number: 0508 • ACR Convergence 2021
The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation
Nozima Aripova, Michael Duryee, Evan Ryan, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In rheumatoid arthritis (RA), chronic synovial inflammation is accompanied by fibrotic responses that together lead to pannus formation and progressive joint damage. Exposure to…
Abstract Number: 1001 • ACR Convergence 2021
Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Rajan Bhandari¹, Heetaek Yang², Noelle Kosarek³, Michael Whitfield⁴ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Geisel School of Medicine, Hanover, NH, ³Dartmouth Geisel School of Medicine, Hartford, VT, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Prior work demonstrates that macrophages (MØs) from patients with Systemic Sclerosis (SSc) produce fibrotic and pro-inflammatory mediators and that cocultured MØs and SSc fibroblasts…
Abstract Number: 1426 • ACR Convergence 2021
Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
Marcela Ferrada¹, Sinisa Savic², Hugh Alessi³, Daniela Ospina⁴, Lorena Wilson⁵, Wendy Goodspeed⁶, Tannaz Kermani⁷, Kenneth Warrington⁸, Matthew Koster⁸, Bhavisha Patel⁹, Patrycja Hoffmann¹⁰, James Poulter¹¹, Rachel Tattersall¹², Amanda Ombrello¹, Christopher Duncan¹³, Elspeth Payne¹⁴, Karoline Krause¹⁵, Hanna Bonnekoh¹⁶, Daniel Kastner¹⁷, Peter Grayson¹⁸ and David Beck¹, ¹National Institutes of Health, Bethesda, MD, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³National Institutes of Health, Bethesda, Maryland, ⁴NIH/NHGRI, Bethesda, MD, ⁵National Institutes of Health, Silver Spring, MD, ⁶National Institutes of Health (NIH), Bethesda, MD, ⁷University of California Los Angeles, Los Angeles, CA, ⁸Mayo Clinic, Rochester, MN, ⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ¹⁰National Institutes of Health, Vienna, VA, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Sheffield Teaching Hospitals NHS Foundation, Sheffield, United Kingdom, ¹³Translational and Clinical Research institute, Immunity and Inflammation Theme, Newcastle, United Kingdom, ¹⁴University College London, Cancer Institute, London, United Kingdom, ¹⁵Department of Dermatology and Allergy, Charité, Berlin, Germany, ¹⁶Department of Dermatology and Allergy, Charité, Berlin, United Kingdom, ¹⁷National Human Genome Research Institute, Bethesda, MD, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined disease cause by myeloid-restricted somatic mutations in blood. Missense mutations at codon…
Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Peter C Taylor¹, Andrew G Bushmakin², Joseph C Cappelleri², Pamela Young³, Rebecca Germino², Joseph Merola⁴ and Gil Yosipovitch⁵, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵University of Miami Miller School, Florida, FL
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
Abstract Number: 0055 • ACR Convergence 2021
Time Course of Intestinal Permeability and Intestinal Inflammation in Rat Adjuvant-induced Arthritis
Sophie Hecquet¹, Perle Totoson², Marie-Paule Algros³, Hélène Martin², Célian Peyronnel², Maude Tournier², Clement Prati¹, Daniel Wendling¹, Céline Demougeot² and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, ³Service d'anatomopathologie, CHU de Besançon, Besançon, France
Background/Purpose: Intestinal inflammation (I-Inf) and increased intestinal permeability (IP) and intestinal damage (ID) have been observed in patients with spondyloarthritis (SpA). However, whether these changes…
Abstract Number: 0511 • ACR Convergence 2021
Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B
Jorge Romo-Tena¹, Jose Esparza-Lopez², Carmelo Carmona-Rivera³, Luz P blanco³, Mariana Kaplan⁴ and María de Jesús Ibarra-Sánchez², ¹INNSZ / NIAMS, Mexico City, Mexico, ²INNSZ, Mexico City, Mexico, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
Abstract Number: 1006 • ACR Convergence 2021
MAA Modified and/or Citrullinated Proteins Stimulate Macrophages and Human Fibroblast-Like Synoviocytes to Increase the Secretion/Expression of Fractalkine Ligand (CX3CL1) and Fractalkine Receptor (CX3CR1)
Nozima Aripova, Michael Duryee, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In rheumatoid arthritis (RA) synovium, activated synovial fibroblasts and macrophages release inflammatory mediators that affect surrounding cells and accelerate disease progression. One such chemokine…
Abstract Number: 1439 • ACR Convergence 2021
Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses
Nafeeza Hafeez, Jimmy Zhong, Jared Steranka, Margit Hagel, Greg Bisacchi, Donna Romero, Rosana Kapeller, Dennis Zaller and Wenyan Miao, Rome Therapeutics, Cambridge, MA
Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…
Abstract Number: 1835 • ACR Convergence 2021
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Joseph Merola¹, Iain McInnes², Atul Deodhar³, Erhard Quebe-Fehling⁴, Maher Aassi⁴, Michael Peine⁴ and Nehal Mehta⁵, ¹Department of Dermatology and Department of Medicine, Division of Rheumatology; Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…
Abstract Number: 0084 • ACR Convergence 2021
COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
Leanna Wise¹, Lauren Mathias², Wendy Mack², Aarya Kafi³, Yash Kothari², Omkar Rao³ and William Stohl⁴, ¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ²University of Southern California, Los Angeles, CA, ³University of California San Diego, San Diego, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: A substantial number of patients with COVID-19 pneumonia develop a hyperinflammatory state. The anti-IL-6 receptor (IL-6R) mAb tocilizumab (TCZ) has been used in such…
Abstract Number: 0527 • ACR Convergence 2021
Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
Abstract Number: 1013 • ACR Convergence 2021
SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
Kate Webb¹, Thandeka Moyo-Gwete², Simon Mendelsohn³, Claire Butters⁴, Simone Richardson⁵, Heidi Facey-Thomas⁴, Debbie Abrahams⁴, Mashudu Madzivhandila⁵, Zanele Makhado⁵, Frances Ayres⁵, William Horsnell⁶, Neilia Manamela⁵, Richard Baguma³, Stanley Kimbung Mbandi³, Mzwandile Erasmus³, Thomas Scriba³, Liesl Zühlke⁷, Penny Moore⁵, George Kassiotis⁸ and Christiaan Scott⁴, ¹Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, ²National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, ³South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, ⁴Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ⁵National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa, ⁷Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁸Retroviral Immunology, Francis Crick Institute, London, United Kingdom
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
Abstract Number: 1441 • ACR Convergence 2021
Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases
Roland Blanque¹, Kenji Shoji¹, Mia Jans², Florence Marsais¹, Laetitia Furio¹, Maikel Colli², Céline Cottereaux¹, Christelle David¹, Nicolas Houvenaghel², Isabelle Parent¹, An Van de Water², Laetitia Perret¹, Sofia Alves¹, David Amantini¹, Steven Van der Plas³ and René Galien⁴, ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium, ³Formally Galapagos NV, Mechelen, Belgium, ⁴Galapagos NV, Romainvulle, France
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates the signaling from type 1 interferon (IFN), interleukin (IL)-12/IL-23 and the IL-10 family of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].